Appendix A: pCODR Clinician Conflict of Interest Declarations

Please Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Paul Gibson

Name of drug and indication under review: Blinatumomab for Relapsed and Refractory Acute Lymphoblastic Leukemia

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the Information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:
- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
   - [ ] Yes
   - [X] No

   If no, please go to Section B

2. What form of payment did you receive? (Check all that apply.)
   - [ ] Advisory role (e.g., advisory boards, HTA submission advice)
   - [ ] Program or Operating Funding (e.g., website)
   - [ ] Conference attendance
   - [ ] Research/educational grants
   - [ ] Royalties
   - [ ] Travel grants
   - [ ] Gifts
   - [ ] Sponsorship of Events
   - [ ] Honoraria
   - [ ] Other, please specify: ____________________________
3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Section B: Holdings or Other Interests
Have you received or is it in possession of stocks or options of more than $10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No

Section C: Affiliations, personal or commercial relationships
Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

No

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: March 7, 2017  Name: Paul Gibson  Signature: [Signature]

pCODR Clinician Input on a Drug Review  © February 2016 CADTH-pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW 10
Appendix A: pCODR Clinician Conflict of Interest Declarations

Please Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Henrique Bittencourt
Name of drug and indication under review: Blinatumomab

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency—it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
   - Yes
   - No
   If no, please go to Section B

2. What form of payment did you receive? (Check all that apply.)

   - Yes
   - No
   - Advisory role (e.g., advisory boards, HTA submission advice)
   - Conference attendance
   - Royalties
   - Gifts
   - Honoraria
   - Program or Operating Funding (e.g., website)
   - Research/educational grants
   - Travel grants
   - Sponsorship of Events
   - Other, please specify:
3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

| Symbiosis (on behalf of Amgen) - |

Section B: Holdings or Other Interests
Have you received or is it in possession of stocks or options of more than $10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

| No |

Section C: Affiliations, personal or commercial relationships
Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

| No |

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: 2013/02/28
Name: Hérycule Saintencourt
Signature: [Signature]